Asymchem plans investments to further expand new China plant

- Last updated on GMT

CMO Asymchem Laboratories will invest $12m (€9m) in its new China manufacturing facility to add downstream capabilities.

So far Asymchem has invested $20m in the Dunhua, China commercial-scale ingredients facility and is preparing to spend more to expand capabilities. The second two phases of the project are due to end later this year and will equip the site to manufacture APIs (active pharmaceutical ingredients).

We believe that [investing in facilities] is the primary path forward in maintaining competitiveness as the global market evens out across the international and domestic Chinese intermediates and API markets​”, Hao Hong, CEO of Asymchem, said.

Related topics: Contract Manufacturing

Related news

Show more